Compounded Sterile Injectable Recalled Due to Lack of Sterility Assurance
Nephron Sterile Compounding Center LLC is recalling 2210 syringes of a three-drug compounded injectable due to lack of assurance of sterility.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The product is a sterile injectable where contamination poses significant risk to patient safety; however, no illnesses or injuries have been reported. Under the rubric, this is a 'risk-of-harm product where injury has not yet been reported,' warranting a High severity score.
Plain-English summary
Nephron Sterile Compounding Center LLC is recalling 2210 pre-filled syringes of a compounded sterile injectable containing ropivacaine HCl, clonidine HCl, and ketorolac tromethamine. Affected lot numbers are RP2003A and RP2003B, both expiring July 20, 2022. The product was distributed nationwide in the United States.
The recall is being issued due to lack of assurance of sterility of the compounded product. This issue involves the manufacturing process for the injectable medication.
Healthcare facilities and practitioners that received this product should discontinue use of affected lots and contact Nephron Sterile Compounding Center LLC for return and replacement guidance.
The recalled product
- Product
- Ropivacaine HCl 123 mg (2.46 mg/mL), Clonidine HCl 0.04 mg (0.0008 mg/mL), Ketorolac Tromethamine 15 mg (0.3 mg/mL) Injection, 50 mL syringe, packaged in 5 x 50 mL Pre-Filled Syringes per carton, 6 x 5 Syringe Carton per case, Rx Only, Nephron 503B outsourcing facility, 4500 12th
- Manufacturer
- Nephron Sterile Compounding Center LLC
- Category
- Drug — Injectable Compounded
- Hazard
- lack-of-sterility
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lots: RP2003A
- Exp. 7/20/2022
- RP2003B
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27